Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
NCT ID: NCT02037529
Last Updated: 2024-08-20
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Clinical Phase
PHASE3
Total Enrollment
201 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-01-17
Study Completion Date
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back. Drugs used in chemotherapy, such as eribulin mesylate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
NCT00915603
Metastatic Breast Cancer
COMPLETED
PHASE2
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
NCT03795012
Breast Cancer
TERMINATED
PHASE2
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NCT01705691
Breast Cancer
HER2-negative Breast Cancer
COMPLETED
PHASE2
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
NCT02061085
Breast Neoplasm
Metastasis
COMPLETED
PHASE2
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
NCT01023204
Breast Cancer
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To demonstrate that patient-reported Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data will be able to detect differences in symptoms between participants treated witheribulin mesylate (eribulin) and standard weekly paclitaxel at 12 weeks.
II. To validate rs7349683 in EPHA5 as a predictor of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel).
SECONDARY OBJECTIVES:
I. To compare overall survival, progression free survival (PFS), objective response rate (ORR), duration of response (DOR), and time to treatment failure (TTF) in patients receiving eribulin versus standard weekly paclitaxel.
II. To compare the 12 month rate of disease progression in patients receiving eribulin versus standard weekly paclitaxel.
III. To evaluate the clinical value and feasibility of collecting patient-reported symptom toxicity information via the Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
IV. To further validate the PRO-CTCAE sensory neuropathy items. V. To compare patient reported neurotoxicity between arms using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) instrument.
VI. To assess the toxicities in patients receiving eribulin versus standard weekly paclitaxel.
CORRELATIVE OBJECTIVES:
I. To compare new metastasis free survival in patients receiving eribulin versus standard weekly paclitaxel.
II. To explore the relationship between common single nucleotide polymorphisms in FGD4, FZD3, and VAC14 as predictors of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel).
III. To evaluate circulating nucleosomes and the apoptosis associated M30 neo-epitope as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general.
VI. To evaluate tubulin isotype expression, mutations, and signaling pathway modifications in tumor tissue as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 12 weeks.
I. To demonstrate that patient-reported Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data will be able to detect differences in symptoms between participants treated witheribulin mesylate (eribulin) and standard weekly paclitaxel at 12 weeks.
II. To validate rs7349683 in EPHA5 as a predictor of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel).
SECONDARY OBJECTIVES:
I. To compare overall survival, progression free survival (PFS), objective response rate (ORR), duration of response (DOR), and time to treatment failure (TTF) in patients receiving eribulin versus standard weekly paclitaxel.
II. To compare the 12 month rate of disease progression in patients receiving eribulin versus standard weekly paclitaxel.
III. To evaluate the clinical value and feasibility of collecting patient-reported symptom toxicity information via the Patient-Report Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
IV. To further validate the PRO-CTCAE sensory neuropathy items. V. To compare patient reported neurotoxicity between arms using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) instrument.
VI. To assess the toxicities in patients receiving eribulin versus standard weekly paclitaxel.
CORRELATIVE OBJECTIVES:
I. To compare new metastasis free survival in patients receiving eribulin versus standard weekly paclitaxel.
II. To explore the relationship between common single nucleotide polymorphisms in FGD4, FZD3, and VAC14 as predictors of peripheral neuropathy from treatment with a microtubule targeting agent (i.e., eribulin or paclitaxel).
III. To evaluate circulating nucleosomes and the apoptosis associated M30 neo-epitope as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general.
VI. To evaluate tubulin isotype expression, mutations, and signaling pathway modifications in tumor tissue as potential biomarkers associated with clinical benefit from treatment with eribulin specifically or the microtubule dynamics inhibitors in general.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 12 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Breast Adenocarcinoma
HER2/Neu Negative
Invasive Breast Carcinoma
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A (eribulin mesylate)
Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Eribulin Mesylate
Intervention Type
DRUG
Given IV
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Quality-of-Life Assessment
Intervention Type
OTHER
Ancillary studies
Arm B (paclitaxel)
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Paclitaxel
Intervention Type
DRUG
Given IV
Quality-of-Life Assessment
Intervention Type
OTHER
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eribulin Mesylate
Given IV
Intervention Type
DRUG
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Paclitaxel
Given IV
Intervention Type
DRUG
Quality-of-Life Assessment
Ancillary studies
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
B1939 Mesylate
E7389
ER-086526
Halaven
Halichondrin B Analog
Anzatax
Asotax
Bristaxol
Praxel
Taxol
Taxol Konzentrat
Quality of Life Assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent document signed and dated by patient
* Histologic confirmation of invasive adenocarcinoma originating in the breast
* Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer \[AJCC\] criteria) not amenable to local therapy
* Clinical or radiographic evidence of disease progression
* Documentation of HER2 negative breast cancer at the time of protocol registration; (Note: HER2 negativity is defined as 0 or 1+ by immunohistochemistry OR nonamplified or equivocal by fluorescence in situ hybridization \[FISH\]; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol)
* Known hormone receptor status at the time of protocol registration; (Note: estrogen receptor \[ER\] and/or progesterone receptor \[PgR\] status are considered positive with a cut-off of \>= 1% invasive tumor cells; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol)
* Patients must demonstrate resolution of all toxicities related to prior chemotherapy, endocrine therapy, targeted therapy, or biologic therapy to grade =\< 1, including peripheral neuropathy, with the exception of alopecia (any grade permissible)
* No more than one prior chemotherapy regimen for advanced or metastatic breast cancer is allowed; prior chemotherapy for metastatic disease must have been completed \>= 14 days prior to randomization
* Any single agent therapy, and any combination of cytotoxic, endocrine, biological targeted agents, and/or humanized antibodies, scheduled to be administered as a preplanned treatment, given concomitantly, sequentially or both, is considered one regimen
* Planned neoadjuvant chemotherapy and postoperative adjuvant chemotherapy is considered one regimen
* If the dosing of one or more of the chemotherapy components of a regimen must be reduced for toxicity, the modified version of the original regimen is not considered a new regimen
* If one or more of the chemotherapy components of a regimen must be omitted for toxicity, the modified version of the original regimen is not considered a new regimen
* If one of the chemotherapy components of a regimen must be replaced with another similar drug of the same therapeutic class, the modified version of the original regimen is not considered a new regimen; however, if a new component, dissimilar to any of the original components, is added to the regimen, the modified version is considered a new regimen
* If chemotherapy is interrupted for surgery or radiotherapy and then continues with an unchanged schedule and components, treatment is considered as one regimen despite the interruption
* Prior treatment may include a taxane as per the following criteria:
* Prior taxane (including paclitaxel) in the adjuvant or neoadjuvant setting is allowed, provided that the interval between the completion of (neo)adjuvant therapy and disease recurrence is \> 12 months
* Prior taxane in the metastatic setting is allowed, provided that the agent administered in the metastatic setting was not standard paclitaxel
* Any number of prior endocrine therapies is allowed and must be discontinued prior to randomization
* Any number of biologic therapies (e.g., bevacizumab) or immunotherapies is allowed in the absence of co-administered chemotherapy and must have been completed \>= 28 days prior to randomization
* Prior treatment with an investigational agent is allowed but must have been completed \>= 28 days prior to randomization with resolution of all treatment-related toxicities to grade =\< 1.
* Minor surgical procedures must be completed \>= 7 days prior to randomization with documentation of adequate recovery from associated complications to grade =\< 1; these include (but are not limited to) laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, endoscopic ultrasonography, skin biopsy, percutaneous needle biopsy, and routine dental procedures; as a precautionary measure, it is recommended, but not strictly required, that placement of a central venous access device, thoracentesis, or paracentesis be done 7 days before the initiation of protocol directed chemotherapy with documentation of adequate recovery from associated complications to grade =\< 1
* Major surgical procedures and open biopsies must be completed \>= 28 days prior to randomization with documentation of adequate recovery from associated complications to grade =\< 1
* Prior radiotherapy must be completed \>= 14 days prior to randomization with documentation of adequate recovery from associated toxicities to grade =\< 1
* Treatment with bisphosphonates or denosumab is allowed and recommended per the standard of care
* Therapeutic anticoagulation is allowed for patients on a stable dose of warfarin or low molecular weight heparin
* Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as \>= 1.0 cm by computed tomography (CT) scan or \>= 1.0 cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be \>= 1.5 cm in the short axis when assessed by CT scans with slice thickness =\< 0.5 cm
* Non-measurable lesions include the following: small lesions (longest diameter \< 1.0 cm for all lesions other than pathologic lymph nodes, which are \>= 1.0 cm and \< 1.5 cm in the short axis), bone metastases, pleural effusions, pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, lymphangitis pulmonis, lymphangitis cutis, and abdominal masses not followed by CT or magnetic resonance imaging (MRI)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
* Life expectancy of \> 12 weeks
* Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =\< 28 days of study registration
* Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =\< 28 days of study registration
* Obtained =\< 7 days prior to registration: Absolute neutrophil count \>= 1500/uL
* Obtained =\< 7 days prior to registration: Platelet count \>= 100,000/uL
* Obtained =\< 7 days prior to registration: Hemoglobin \>= 9 g/dL
* Obtained =\< 7 days prior to registration: Total bilirubin =\< 1.5 times the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert?s syndrome
* Obtained =\< 7 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferases \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN except in the case of liver metastases, where =\< 5 x ULN is allowed
* Obtained =\< 7 days prior to registration: Creatinine =\< 2.0 mg/dL or creatinine clearance \> 50 mL/min
* Obtained =\< 7 days prior to registration: Corrected QT (QTc) interval =\< 500 msec on the baseline electrocardiogram
* Negative pregnancy test done =\< 72 hours prior to registration for women of childbearing potential only; Note: all female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation \>= 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy)
* Female subjects of child-bearing potential must agree to use highly effective contraception during the study treatment and for 3 months after the final dose of study treatment; female subjects exempt from this requirement are subjects who practice total abstinence; if currently abstinent, the subject must agree to use a double barrier method of contraception (i.e., condom and occlusive cap \[diaphragm or cervical/vault caps\]) with spermicide or until they are established on highly effective contraception for at least one menstrual cycle if they become sexually active during the study treatment and for 3 months after the final dose of study treatment
* Highly effective contraception includes:
* Placement of intrauterine device or system
* Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicide
* Vasectomized partner with confirmed azoospermia
* Male subjects and their female partner who are of child-bearing potential (as defined above), and are not practicing total abstinence, must agree to use highly effective contraception during study treatment and for 3 months after the final dose of study treatment; if currently abstinent, the subject must agree to use a double barrier method of contraception if they become sexually active, or until they are established on highly effective contraception as described above
* Ability to complete questionnaire(s) independently or with assistance
* Willingness to provide blood and tissue samples for correlative research purposes; (Note: these tissue samples are from archived tissue, if available; new biopsies are not required)
* Ability to comprehend and respond to questions using a telephone keypad
* Histologic confirmation of invasive adenocarcinoma originating in the breast
* Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer \[AJCC\] criteria) not amenable to local therapy
* Clinical or radiographic evidence of disease progression
* Documentation of HER2 negative breast cancer at the time of protocol registration; (Note: HER2 negativity is defined as 0 or 1+ by immunohistochemistry OR nonamplified or equivocal by fluorescence in situ hybridization \[FISH\]; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol)
* Known hormone receptor status at the time of protocol registration; (Note: estrogen receptor \[ER\] and/or progesterone receptor \[PgR\] status are considered positive with a cut-off of \>= 1% invasive tumor cells; status may be defined on the basis of historic results on the breast primary or a metastatic site, whichever is most recent; repeat biopsies are not required for participation in this protocol)
* Patients must demonstrate resolution of all toxicities related to prior chemotherapy, endocrine therapy, targeted therapy, or biologic therapy to grade =\< 1, including peripheral neuropathy, with the exception of alopecia (any grade permissible)
* No more than one prior chemotherapy regimen for advanced or metastatic breast cancer is allowed; prior chemotherapy for metastatic disease must have been completed \>= 14 days prior to randomization
* Any single agent therapy, and any combination of cytotoxic, endocrine, biological targeted agents, and/or humanized antibodies, scheduled to be administered as a preplanned treatment, given concomitantly, sequentially or both, is considered one regimen
* Planned neoadjuvant chemotherapy and postoperative adjuvant chemotherapy is considered one regimen
* If the dosing of one or more of the chemotherapy components of a regimen must be reduced for toxicity, the modified version of the original regimen is not considered a new regimen
* If one or more of the chemotherapy components of a regimen must be omitted for toxicity, the modified version of the original regimen is not considered a new regimen
* If one of the chemotherapy components of a regimen must be replaced with another similar drug of the same therapeutic class, the modified version of the original regimen is not considered a new regimen; however, if a new component, dissimilar to any of the original components, is added to the regimen, the modified version is considered a new regimen
* If chemotherapy is interrupted for surgery or radiotherapy and then continues with an unchanged schedule and components, treatment is considered as one regimen despite the interruption
* Prior treatment may include a taxane as per the following criteria:
* Prior taxane (including paclitaxel) in the adjuvant or neoadjuvant setting is allowed, provided that the interval between the completion of (neo)adjuvant therapy and disease recurrence is \> 12 months
* Prior taxane in the metastatic setting is allowed, provided that the agent administered in the metastatic setting was not standard paclitaxel
* Any number of prior endocrine therapies is allowed and must be discontinued prior to randomization
* Any number of biologic therapies (e.g., bevacizumab) or immunotherapies is allowed in the absence of co-administered chemotherapy and must have been completed \>= 28 days prior to randomization
* Prior treatment with an investigational agent is allowed but must have been completed \>= 28 days prior to randomization with resolution of all treatment-related toxicities to grade =\< 1.
* Minor surgical procedures must be completed \>= 7 days prior to randomization with documentation of adequate recovery from associated complications to grade =\< 1; these include (but are not limited to) laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, endoscopic ultrasonography, skin biopsy, percutaneous needle biopsy, and routine dental procedures; as a precautionary measure, it is recommended, but not strictly required, that placement of a central venous access device, thoracentesis, or paracentesis be done 7 days before the initiation of protocol directed chemotherapy with documentation of adequate recovery from associated complications to grade =\< 1
* Major surgical procedures and open biopsies must be completed \>= 28 days prior to randomization with documentation of adequate recovery from associated complications to grade =\< 1
* Prior radiotherapy must be completed \>= 14 days prior to randomization with documentation of adequate recovery from associated toxicities to grade =\< 1
* Treatment with bisphosphonates or denosumab is allowed and recommended per the standard of care
* Therapeutic anticoagulation is allowed for patients on a stable dose of warfarin or low molecular weight heparin
* Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as \>= 1.0 cm by computed tomography (CT) scan or \>= 1.0 cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be \>= 1.5 cm in the short axis when assessed by CT scans with slice thickness =\< 0.5 cm
* Non-measurable lesions include the following: small lesions (longest diameter \< 1.0 cm for all lesions other than pathologic lymph nodes, which are \>= 1.0 cm and \< 1.5 cm in the short axis), bone metastases, pleural effusions, pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, lymphangitis pulmonis, lymphangitis cutis, and abdominal masses not followed by CT or magnetic resonance imaging (MRI)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
* Life expectancy of \> 12 weeks
* Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =\< 28 days of study registration
* Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including =\< 28 days of study registration
* Obtained =\< 7 days prior to registration: Absolute neutrophil count \>= 1500/uL
* Obtained =\< 7 days prior to registration: Platelet count \>= 100,000/uL
* Obtained =\< 7 days prior to registration: Hemoglobin \>= 9 g/dL
* Obtained =\< 7 days prior to registration: Total bilirubin =\< 1.5 times the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert?s syndrome
* Obtained =\< 7 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferases \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN except in the case of liver metastases, where =\< 5 x ULN is allowed
* Obtained =\< 7 days prior to registration: Creatinine =\< 2.0 mg/dL or creatinine clearance \> 50 mL/min
* Obtained =\< 7 days prior to registration: Corrected QT (QTc) interval =\< 500 msec on the baseline electrocardiogram
* Negative pregnancy test done =\< 72 hours prior to registration for women of childbearing potential only; Note: all female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation \>= 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy)
* Female subjects of child-bearing potential must agree to use highly effective contraception during the study treatment and for 3 months after the final dose of study treatment; female subjects exempt from this requirement are subjects who practice total abstinence; if currently abstinent, the subject must agree to use a double barrier method of contraception (i.e., condom and occlusive cap \[diaphragm or cervical/vault caps\]) with spermicide or until they are established on highly effective contraception for at least one menstrual cycle if they become sexually active during the study treatment and for 3 months after the final dose of study treatment
* Highly effective contraception includes:
* Placement of intrauterine device or system
* Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicide
* Vasectomized partner with confirmed azoospermia
* Male subjects and their female partner who are of child-bearing potential (as defined above), and are not practicing total abstinence, must agree to use highly effective contraception during study treatment and for 3 months after the final dose of study treatment; if currently abstinent, the subject must agree to use a double barrier method of contraception if they become sexually active, or until they are established on highly effective contraception as described above
* Ability to complete questionnaire(s) independently or with assistance
* Willingness to provide blood and tissue samples for correlative research purposes; (Note: these tissue samples are from archived tissue, if available; new biopsies are not required)
* Ability to comprehend and respond to questions using a telephone keypad
Exclusion Criteria
* Prior malignancy, other than carcinoma in situ of the cervix and non-melanoma skin cancers, unless the prior malignancy was diagnosed and definitively treated \>= 5 years previously, there is no subsequent evidence of recurrence, and the patient is considered by a physician to be at \< 30% risk of relapse
* Any of the following:
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception
* Presence of a serious nonhealing wound, ulcer, or bone fracture
* History of Common Terminology Criteria for Adverse Events (CTCAE) grade \>= 3 hypersensitivity to paclitaxel or Cremophor EL
* Pre-existing peripheral neuropathy grade ?= 2 at registration
* Significant cardiovascular impairment (e.g., New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia)
* Subjects with known positive human immunodeficiency virus (HIV) status
* History of stroke or transient ischemic attack =\< 6 months prior to registration
* History of uncontrolled seizures; (Note: patients are eligible for the study if the seizures are well controlled with standard medications)
* Severe or uncontrolled intercurrent illness/infection
* Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer
* Prior exposure to eribulin mesylate
* Any of the following:
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception
* Presence of a serious nonhealing wound, ulcer, or bone fracture
* History of Common Terminology Criteria for Adverse Events (CTCAE) grade \>= 3 hypersensitivity to paclitaxel or Cremophor EL
* Pre-existing peripheral neuropathy grade ?= 2 at registration
* Significant cardiovascular impairment (e.g., New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia)
* Subjects with known positive human immunodeficiency virus (HIV) status
* History of stroke or transient ischemic attack =\< 6 months prior to registration
* History of uncontrolled seizures; (Note: patients are eligible for the study if the seizures are well controlled with standard medications)
* Severe or uncontrolled intercurrent illness/infection
* Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer
* Prior exposure to eribulin mesylate
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Academic and Community Cancer Research United
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minetta C Liu
Role: PRINCIPAL_INVESTIGATOR
Academic and Community Cancer Research United
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Site Status
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Site Status
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Site Status
Mayo Clinic in Florida
Jacksonville, Florida, United States
Site Status
University of Illinois
Chicago, Illinois, United States
Site Status
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site Status
Illinois CancerCare-Peoria
Peoria, Illinois, United States
Site Status
Carle Cancer Center NCI Community Oncology Research Program
Urbana, Illinois, United States
Site Status
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, United States
Site Status
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, United States
Site Status
Siouxland Regional Cancer Center
Sioux City, Iowa, United States
Site Status
Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
Site Status
Ochsner NCI Community Oncology Research Program
New Orleans, Louisiana, United States
Site Status
Lafayette Family Cancer Center-EMMC
Brewer, Maine, United States
Site Status
Cancer Research Consortium of West Michigan NCORP
Grand Rapids, Michigan, United States
Site Status
Essentia Health NCI Community Oncology Research Program
Duluth, Minnesota, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, United States
Site Status
University of Missouri - Ellis Fischel
Columbia, Missouri, United States
Site Status
Heartland Regional Medical Center
Saint Joseph, Missouri, United States
Site Status
Washington University School of Medicine
St Louis, Missouri, United States
Site Status
Heartland Cancer Research CCOP
St Louis, Missouri, United States
Site Status
Cancer Alliance of Nebraska
Omaha, Nebraska, United States
Site Status
University of Nebraska Medical Center
Omaha, Nebraska, United States
Site Status
New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire, United States
Site Status
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Site Status
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, United States
Site Status
Mission Hospital-Saint Joseph Campus
Asheville, North Carolina, United States
Site Status
Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina, United States
Site Status
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Site Status
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, United States
Site Status
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, United States
Site Status
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, United States
Site Status
Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, United States
Site Status
Providence Portland Medical Center
Portland, Oregon, United States
Site Status
Women and Infants Hospital
Providence, Rhode Island, United States
Site Status
Rapid City Regional Hospital
Rapid City, South Dakota, United States
Site Status
Edwards Comprehensive Cancer Center
Huntington, West Virginia, United States
Site Status
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-02048
Identifier Type: REGISTRY
Identifier Source: secondary_id
RU011201I
Identifier Type: OTHER
Identifier Source: secondary_id
RU011201I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
NCT06857305
ENROLLING_BY_INVITATION
PHASE3
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
NCT01401959
COMPLETED
PHASE2
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
NCT02040857
COMPLETED
PHASE2
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
NCT01269346
COMPLETED
PHASE2
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
NCT01795586
COMPLETED
PHASE1
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
NCT00353717
UNKNOWN
PHASE1/PHASE2
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
NCT06308939
NOT_YET_RECRUITING
PHASE2
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT03709082
TERMINATED
PHASE1/PHASE2
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT06062498
RECRUITING
PHASE2
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
NCT02175446
UNKNOWN
PHASE2
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
NCT01276769
UNKNOWN
PHASE2
Eribulin in HER2 Negative Metastatic BrCa
NCT01827787
COMPLETED
PHASE2
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
NCT02120469
COMPLETED
PHASE1
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00030537
COMPLETED
PHASE2
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
NCT01427933
COMPLETED
PHASE2
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
NCT02513472
COMPLETED
PHASE1/PHASE2
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
NCT03393741
TERMINATED
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287
ACTIVE_NOT_RECRUITING
PHASE2
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT02623972
ACTIVE_NOT_RECRUITING
PHASE2
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
NCT02514681
COMPLETED
PHASE3
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03579472
TERMINATED
PHASE1
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00042809
COMPLETED
PHASE1
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
NCT00193622
COMPLETED
PHASE2
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
NCT01980277
TERMINATED
PHASE1/PHASE2